1365 related articles for article (PubMed ID: 24215799)
21. Localization of orexin B and orexin-2 receptor in the rat epididymis.
Liguori G; Tafuri S; Miyoshi C; Yanagisawa M; Squillacioti C; De Pasquale V; Mirabella N; Vittoria A; Costagliola A
Acta Histochem; 2018 Apr; 120(3):292-297. PubMed ID: 29496265
[TBL] [Abstract][Full Text] [Related]
22. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism.
Dugovic C; Shelton JE; Yun S; Bonaventure P; Shireman BT; Lovenberg TW
Front Neurosci; 2014; 8():28. PubMed ID: 24592208
[TBL] [Abstract][Full Text] [Related]
23. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms.
Tang S; Huang W; Lu S; Lu L; Li G; Chen X; Liu X; Lv X; Zhao Z; Duan R; Du Y; Tang J
Peptides; 2017 Feb; 88():55-61. PubMed ID: 27988352
[TBL] [Abstract][Full Text] [Related]
24. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders.
Xu TR; Yang Y; Ward R; Gao L; Liu Y
Cell Signal; 2013 Dec; 25(12):2413-23. PubMed ID: 23917208
[TBL] [Abstract][Full Text] [Related]
25. Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat.
Steiner MA; Sciarretta C; Brisbare-Roch C; Strasser DS; Studer R; Jenck F
Psychoneuroendocrinology; 2013 Apr; 38(4):560-71. PubMed ID: 22917622
[TBL] [Abstract][Full Text] [Related]
26. The physiological role of orexins.
Martynska L; Wolinska-Witort E; Chmielowska M; Bik W; Baranowska B
Neuro Endocrinol Lett; 2005 Aug; 26(4):289-92. PubMed ID: 16135995
[TBL] [Abstract][Full Text] [Related]
27. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
[TBL] [Abstract][Full Text] [Related]
28. Distinct effects of IPSU and suvorexant on mouse sleep architecture.
Hoyer D; Dürst T; Fendt M; Jacobson LH; Betschart C; Hintermann S; Behnke D; Cotesta S; Laue G; Ofner S; Legangneux E; Gee CE
Front Neurosci; 2013; 7():235. PubMed ID: 24368893
[TBL] [Abstract][Full Text] [Related]
29. [Connectomics of orexin-producing neurons: analysis using mouse models].
Sakurai T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):223-9. PubMed ID: 22256611
[TBL] [Abstract][Full Text] [Related]
30. Orexin A and B in vitro modify orexins receptors expression and gonadotropins secretion of anterior pituitary cells of proestrous rats.
Cataldi NI; Lux Lantos VA; Libertun C
Regul Pept; 2014 Jan; 188():25-30. PubMed ID: 24333629
[TBL] [Abstract][Full Text] [Related]
31. Suvorexant for the treatment of insomnia.
Jacobson LH; Callander GE; Hoyer D
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
[TBL] [Abstract][Full Text] [Related]
32. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
[TBL] [Abstract][Full Text] [Related]
33. Structure-based development of a subtype-selective orexin 1 receptor antagonist.
Hellmann J; Drabek M; Yin J; Gunera J; Pröll T; Kraus F; Langmead CJ; Hübner H; Weikert D; Kolb P; Rosenbaum DM; Gmeiner P
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18059-18067. PubMed ID: 32669442
[TBL] [Abstract][Full Text] [Related]
34. Profile of suvorexant in the management of insomnia.
Sutton EL
Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
36. Toward the Mysteries of Sleep.
Yanagisawa M
Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
[TBL] [Abstract][Full Text] [Related]
37. Opposite effects of sleep rebound on orexin OX1 and OX2 receptor expression in rat brain.
D'Almeida V; Hipólide DC; Raymond R; Barlow KB; Parkes JH; Pedrazzoli M; Tufik S; Nobrega JN
Brain Res Mol Brain Res; 2005 May; 136(1-2):148-57. PubMed ID: 15893599
[TBL] [Abstract][Full Text] [Related]
38. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
39. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.
Han Y; Yuan K; Zheng Y; Lu L
Neurosci Bull; 2020 Apr; 36(4):432-448. PubMed ID: 31782044
[TBL] [Abstract][Full Text] [Related]
40. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.
Mahoney CE; Mochizuki T; Scammell TE
Sleep; 2020 Jun; 43(6):. PubMed ID: 31830270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
